ESTRO 2025 - Abstract Book

S3760

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2025

Results: The optimal cut-off value is determined as 0.538, by which 121/240 (50.41%) and 119/240 (49.58%) patients were identified as TSR – and TSR + , respectively. Across the whole cohort, no significant difference was found between the patients with TSR – and TSR + in DFS (HR=1.02, 95%CI: 0.67-1.55, p=0.917) or OS (HR=1.08, 95%CI: 0.63-1.85, p=0.774). However, TSR + patients who received IrCRT had significantly longer DFS (HR=0.33, 95%CI: 0.17-0.63, p<0.005) and OS (HR=0.42, 95%CI: 0.18-0.96, p=0.032) than TSR + patients receiving CRT ( Figure 2A ). No evidence of differential treatment effect was observed in TSR – patients ( Figure 2B ), with IrCRT vs CRT in this group for DFS (HR=1.16, 95%CI: 0.64-2.11, p=0.626) or OS (HR=1.66, 95%CI: 0.76-3.61, p=0.199).